I thought they succeeded in this mosquito thing some years ago. Or were they just fear mongering then....too? Bats and birds will drop dead, as well, I would think.
The Bill & Melinda Gates Foundation and CureVac today announced that the foundation has made a commitment to invest $52 million (€46 million) in CureVac, a leading clinical-stage biopharmaceutical company specializing in mRNA-based vaccine technologies. As part of the agreement, the foundation will also provide separate funding for several projects to develop prophylactic vaccines based on CureVac’s proprietary messenger RNA (mRNA) platform. In addition, CureVac’s longstanding investor dievini Hopp BioTech announced a commitment of $24 million (€21 million) of additional equity.
CureVac is pioneering the use of natural and chemically unmodified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. CureVac’s novel technology is the broadest and most advanced mRNA therapeutic platform and allows for rapid, low-cost production of multiple drugs and vaccines. Additionally, CureVac’s mRNA vaccines are thermostable, which eliminates the demand for cold-chain storage and infrastructure, a major challenge in the vaccine supply of most developing countries.
The investment will support continued development of CureVac’s platform technology and the construction of an industrial scale Good Manufacturing Practice (GMP) production facility. As part of this partnership, CureVac and the Gates Foundation will collaborate on the development and production of numerous vaccines against infectious diseases that disproportionately affect people in the world’s poorest countries.
- SATAN , WE BIND YOU, AND, ALL YOUR DESTROYING DEMONS, AND, SEND YOU ALL BACK TO HELL WHERE YOU CAME FROM, NEVER TO RETURN AGAIN, IN JESUS’ PRECIOUS HOLY NAME …!!! HALLELUJAH … FOR JESUS CHRIST, THE ONLY BEGOTTEN SON OF GOD…!!
They are really focussing on getting more pharma in African people; they have just started the rollout of the malaria vaccine. I predict the next fake virus that mostly kills children will come from Africa.
Don't know how to link a Substack as it keeps going to notes which I only recently subscribed to.
Anyway Geoff Pain MD has a just now Substack with Elon petting his Trump dog.
It's a must see.
It's about a possible mass burning of maga merchandise
Paging a Catholic priest -https://youtu.be/gVtKR4pwlDw. Savonarola and the Bonfires of the Vanities.
O' course with this White House a Lubavitcher Rebbe who is A.I. instead presides.
I thought they succeeded in this mosquito thing some years ago. Or were they just fear mongering then....too? Bats and birds will drop dead, as well, I would think.
I think they did and this is upgrade. Mosquito 3.0
Business. CureVac.
Elon Musk shares details about Tesla’s mRNA microfactories for CureVac
https://teslarati.com/elon-musk-shares-tesla-mrna-microfactories-details/
CureVac (Sanofi Pasteur, In-Cell-Art, DARPA, Gates Foundation, CEPI, vaccine printer, University of Wisconsin, Tesla)
(November 15, 2011) CureVac, Sanofi Pasteur, and In-Cell-Art Collaborate on €33.1M DARPA-Supported Vaccine Program
CureVac and Sanofi Pasteur have signed a potentially €150 million-plus vaccine development
option agreement in parallel with initiating a $33.1 million Defence Advanced Research Projects Agency (DARPA)
co-funded collaboration with In-Cell-Art, focused on developing vaccines against infectious diseases based on CureVac’s RNActive® technology.
The four-year DARPA-supported program will exploit CureVac’s RNActive technology along with In-Cell-Art’s nanoparticle expertise
and Sanofi’s vaccine development capabilities.
Under terms of this option, if exercised, CureVac could receive up to €101.5 million
in up-front and milestone payments, plus royalties, if Sanofi Pasteur develops either a prophylactic or therapeutic vaccine against each pathogen,
and up to €150.5 million if Sanofi Pasteur develops both a prophylactic and a therapeutic vaccine.
The latter would be responsible for funding all R&D activities, and would have exclusive global marketing rights for RNActive vaccines
selected under the option. CureVac would, in turn, retain the rights to its own core development programs
and to the background technology for all applications outside those encompassed by the Sanofi Pasteur option.
[link to www.genengnews.com (secure)]
(July 1, 2014) CureVac Signs an Exclusive License Agreement with Sanofi Pasteur to Develop and Commercialize an mRNA-based Prophylactic Vaccine
CureVac, a German clinical-stage biopharmaceutical company, today announced the execution of an exclusive license agreement with Sanofi Pasteur S.A.,
the vaccines division of Sanofi (EURONEXT: SAN andNYSE: SNY), to develop and commercialize an mRNA-based vaccine against an undisclosed pathogen.
In 2011, CureVac and Sanofi Pasteur signed a collaboration and license option agreement for several pre-defined pathogens.
CureVac met all pre-agreed milestones and acceptance criteria relating to these agreements,
and therefore Sanofi Pasteur exercised its first option and extended its exclusive and non-exclusive options on all five pathogens.
[link to www.prnewswire.com (secure)]
(November 2, 2015) Gates, Hopp back $110M megaround for CureVac's mRNA work
The Bill & Melinda Gates Foundation joined German billionaire Dietmar Hopp
in a venture syndicate that is injecting a whopping $110 million of fresh funds into CureVac,
a German mRNA biotech which has now garnered some $330 million in support.
Baillie Gifford led the round, joined by the billionaires, Chartwave Limited, Coppel Family, Elma Investments (formerly Northview) and Sigma Group.
CureVac has several different tech platforms in play, ranging from stimulating the immune system
to an mRNA approach designed to coax cells to produce their own protein therapeutics.
[link to www.fiercebiotech.com (secure)]
(February 27, 2019) CEPI, CureVac team up in $34M deal to advance RNA vaccine 'printer'
Since it formed two years ago, the global outbreak preparedness group CEPI has invested hundreds of millions of dollars in vaccine
candidates against infectious diseases. Now, it’s back at it with CureVac in a deal to help the biotech advance its mRNA vaccine "printer."
After preclinical work, the partners aim to advance two vaccine candidates against named diseases into phase 1 testing.
Along the way, CureVac will continue collaborating with its existing partners, including the University of Wisconsin.
CEPI’s grant to CureVac is one in a series of investments the global preparedness group has made.
Formed in 2017, the group initially focused on Lassa, MERS and Nipah viruses, but more recently
has sought partners to work on vaccine platforms against unknown pathogens,
plus Rift Valley fever virus and Chikungunya.
[link to www.fiercepharma.com (secure)]
(August 13, 2019) CureVac and Yale Team Up for mRNA-Based Lung Therapies
Tubingen, Germany-based CureVac has entered a Collaboration Research Agreement with Yale University to focus on lung therapies.
Under the terms of the deal with Yale University, Yale researchers led by Geoff Chupp
will conduct discovery research on targets associated with pulmonary diseases,
then turn over the candidates to CureVac for preclinical and clinical development.
CureVac will fund all the discovery research and hold the acquisition options to rights for the targets.
So far, CureVac has raised about $420 million in equity investments,
including backing from The Bill & Melinda Gates Foundation,
which has a significant interest in vaccine development.
[link to www.pharmalive.com (secure)]
(July 2, 2020) Tesla teams up with CureVac to make 'RNA microfactories' for COVID-19 shot, Elon Musk says
Tesla CEO Elon Musk tweeted Thursday that the electric carmaker had signed on with CureVac to make portable molecular RNA printers—
what Musk called "RNA microfactories"— to help produce doses of the German vaccine maker's COVID-19 shot candidate.
Musk said his company was working on the printers as a "side project" and could take on additional partners in the future.
CureVac has previously touted its work on portable "printers" for its mRNA-based vaccines,
which would allow the company to produce shots at scale in farflung locations without the standard logistical concerns.
CureVac's printers are designed to quickly create mRNA vaccine candidates against known pathogens,
plus new and unknown diseases, a category the World Health Organization calls “Disease X.”
If successful, the printers could also be used for CureVac's COVID-19 shot candidate, CVnCoV,
which received German and Belgian regulatory clearance to enter phase 1 human testing in mid-June.
The start of the 168-subject study comes days after the German government invested $337 million
in CureVac to support its efforts to develop and manufacture a vaccine against the coronavirus.
[link to www.fiercebiotech.com (secure)]
(July 3, 2020) Tesla filed joint patent with CureVac on possibly revolutionary ‘bioreactor for RNA’
A patent application shows that Tesla has been working with CureVac on a possibly revolutionary “bioreactor for RNA” for over a year.
It took many by surprise since it seems like Tesla is making a move in the biotech world,
but we now learn that it has been in the works for a long time — even pre-COVID-19.
The patent application is called “Bioreactor for RNA in vitro Transcription” and it describes an automated system for RNA manufacturing.
It describes a problem with current manufacturing processes for RNA molecules being labor extensive and requiring several different equipments.
The Tesla/CureVac solution solves those problems.
[link to electrek.co (secure)]
The Bill & Melinda Gates Foundation and CureVac today announced that the foundation has made a commitment to invest $52 million (€46 million) in CureVac, a leading clinical-stage biopharmaceutical company specializing in mRNA-based vaccine technologies. As part of the agreement, the foundation will also provide separate funding for several projects to develop prophylactic vaccines based on CureVac’s proprietary messenger RNA (mRNA) platform. In addition, CureVac’s longstanding investor dievini Hopp BioTech announced a commitment of $24 million (€21 million) of additional equity.
CureVac is pioneering the use of natural and chemically unmodified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. CureVac’s novel technology is the broadest and most advanced mRNA therapeutic platform and allows for rapid, low-cost production of multiple drugs and vaccines. Additionally, CureVac’s mRNA vaccines are thermostable, which eliminates the demand for cold-chain storage and infrastructure, a major challenge in the vaccine supply of most developing countries.
The investment will support continued development of CureVac’s platform technology and the construction of an industrial scale Good Manufacturing Practice (GMP) production facility. As part of this partnership, CureVac and the Gates Foundation will collaborate on the development and production of numerous vaccines against infectious diseases that disproportionately affect people in the world’s poorest countries.
- SATAN , WE BIND YOU, AND, ALL YOUR DESTROYING DEMONS, AND, SEND YOU ALL BACK TO HELL WHERE YOU CAME FROM, NEVER TO RETURN AGAIN, IN JESUS’ PRECIOUS HOLY NAME …!!! HALLELUJAH … FOR JESUS CHRIST, THE ONLY BEGOTTEN SON OF GOD…!!
Ivermectin kills the parasite. RETURN TO EPSTEIN ISLAND BILL!
Do you think that ivermectin will kill parasite Musk and Gates and Trump et al.
They are really focussing on getting more pharma in African people; they have just started the rollout of the malaria vaccine. I predict the next fake virus that mostly kills children will come from Africa.
I'm not automatically believing this Gates malarkey.
Really though, Gates should be arrested for what he has financed.
Heard something about some teenage pranksters who sprayed supermarket fruit and vegetables with fly spray and they got the book thrown at them.
Must and Gates are so brazen, even if both liars. Having Trump's ear they are invincible.
Wonder what the pecking order is.
What is the connection/similarity you see between Musk and Gates?